<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560962</url>
  </required_header>
  <id_info>
    <org_study_id>blepharitis</org_study_id>
    <nct_id>NCT01560962</nct_id>
  </id_info>
  <brief_title>Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis</brief_title>
  <official_title>Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <brief_summary>
    <textblock>
      Objective: To determine the preliminary outcome of external over the counter (OTC) povidone&#xD;
      iodine (PI) application in the management of chronic and acute blepharitis vs. currently&#xD;
      clinically accepted medical regimen, i.e. eyelid hygiene, antibiotic drops, or&#xD;
      antibiotic/steroid ointments.&#xD;
&#xD;
      Methodology: One hundred adult patients with chronic and acute blepharitis will be enrolled&#xD;
      and randomized into four groups.&#xD;
&#xD;
      In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI&#xD;
      twice daily for 10 days and the other eye with no intervention.&#xD;
&#xD;
      In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI&#xD;
      and the other eye will receive warm soaked eyelid wash.&#xD;
&#xD;
      In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI&#xD;
      and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10&#xD;
      days.&#xD;
&#xD;
      In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI&#xD;
      and the other eye will receive tobradex ointment applied to the lid margin.&#xD;
&#xD;
      Subjective variables assessed included itchiness, foreign body sensation and eyelid edema&#xD;
      (grade 0-4). Objective variables assessed included lid margin redness, meibomian gland&#xD;
      plugging and presence/absence of collarets (grade 0-4). Cultures of lid margin at the&#xD;
      initiation and at the cessation of treatment were obtained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Final statiscial analysis for subjective and objective numerical values following treatment&#xD;
      for each group of subjects (group 2,3,4) should show equal or almost equal efficacy in&#xD;
      treatment of blepharitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    research staffs unable to continue.&#xD;
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>meibomian gland plugging</measure>
    <time_frame>01/12 to 01/13</time_frame>
    <description>Variables of interest will include:&#xD;
A. Subjective Measures including patient-rated symptom scores for 1. Itching (grade 0-3) 2. foreign body sensation (grade 0-3) 3. ocular dryness (grade 0-3) 4. ocular burning (grade 0-3) and 5. swollen eyelids (grade 0-3) B. Objective Measures: Evaluation of 1. lid margin redness (grade 0-3) 2. meibomian gland plugging (grade 0-3) and 3. Presence of collarets and scurfs (Grade 0-3) 4. Cultures of eyelid margin at the start and at the conclusion of treatment at 10 days.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>PI vs no intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI vs hygiene</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI vs azasite</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI vs tobradex</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>povidone iodine</intervention_name>
    <description>over the counter (OTC) 5% povidone iodine (PI)</description>
    <arm_group_label>PI vs azasite</arm_group_label>
    <arm_group_label>PI vs hygiene</arm_group_label>
    <arm_group_label>PI vs no intervention</arm_group_label>
    <arm_group_label>PI vs tobradex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <arm_group_label>PI vs no intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <arm_group_label>PI vs azasite</arm_group_label>
    <other_name>Azasite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin-dexmethasone</intervention_name>
    <arm_group_label>PI vs tobradex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>warm soaked eyelid wash</intervention_name>
    <arm_group_label>PI vs hygiene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All potential subjects with symptomatic blepharitis examined to have blepharitis with&#xD;
             healthy mental status, able to give consent, with/without co-existing medical&#xD;
             consitions will be considered.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All subjects with history and/or probable history of allergic reaction to&#xD;
             povidine-iodine, azithromycin, &amp; tobramycin/dexamethasone and all subjects who have&#xD;
             mental disability and are unable to give direct consent will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Veterans Affairs Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

